应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BCAX Bicara Therapeutics
未开盘 09-26 16:00:00 EDT
25.70
-0.60
-2.28%
盘后
25.70
+0.00
0.00%
16:00 EDT
最高
26.70
最低
24.65
成交量
22.49万
今开
26.70
昨收
26.30
日振幅
7.79%
总市值
13.30亿
流通市值
4.50亿
总股本
5,176万
成交额
574.45万
换手率
1.29%
流通股本
1,750万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨
Reuters · 09-14
BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨
更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46
Reuters · 09-14
更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
异动解读 · 09-14
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%
Reuters · 09-14
由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%
更新 2-Zenas 生物制药公司首次上市股价上涨近 8
Reuters · 09-14
更新 2-Zenas 生物制药公司首次上市股价上涨近 8
TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元
Reuters · 09-13
TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元
加载更多
公司概况
公司名称:
Bicara Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。
发行价格:
--
{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":25.7,"timestamp":1727380800000,"preClose":26.3,"halted":0,"volume":224905,"hourTrading":{"tag":"盘后","latestPrice":25.7,"preClose":25.7,"latestTime":"16:00 EDT","volume":524,"amount":13466.8,"timestamp":1727380801285},"delay":0,"floatShares":17500000,"shares":51760925,"eps":0,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.6,"latestTime":"09-26 16:00:00 EDT","open":26.7,"high":26.7,"low":24.65,"amount":5744474.93052,"amplitude":0.077947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1727424000000},"adr":0,"listingDate":1726200000000,"adjPreClose":26.3,"preHourTrading":{"tag":"盘前","latestPrice":26.54,"preClose":26.3,"latestTime":"09:29 EDT","volume":113,"amount":2999.23018,"timestamp":1727357379058},"postHourTrading":{"tag":"盘后","latestPrice":25.7,"preClose":25.7,"latestTime":"16:00 EDT","volume":524,"amount":13466.8,"timestamp":1727380801285},"volumeRatio":0.544269},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"2467702802","title":"BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2467702802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467702802?lang=zh_cn&edition=full","pubTime":"2024-09-14 02:20","pubTimestamp":1726251654,"startTime":"0","endTime":"0","summary":" 9月13日 - ** 癌症疗法开发商 Bicara Therapeutics 在纳斯达克首次上市时股价大涨 50%,最后上涨 39%,报收于 25.02 美元。* * 由另类资产管理公司 TPG 支持的 Bicara,通过出售 1750 万股股票筹集了 3.15 亿美元,其定价为市场范围的上限。我们可以从今天上市的另外两家公司 中看到明显的迹象,这两家公司都提高了发行规模--IPOX 研究分析师 Lukas Muehlbauer 说。** 摩根士丹利、TD Cowen、Stifel 和 Cantor Fitzgerald 为承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BK4139","SQQQ","BK4135","NQmain","TQQQ","QLD","ARTL",".IXIC","QID","TPG","PSQ","BK4007","BCAX","LENZ"],"gpt_icon":1},{"id":"2467093437","title":"更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46","url":"https://stock-news.laohu8.com/highlight/detail?id=2467093437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467093437?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:22","pubTimestamp":1726248149,"startTime":"0","endTime":"0","summary":" 路透9月13日 - 周五,Bicara Therapeutics 首次上市时股价大涨近46%,表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。公司股票开盘价为每股26.25美元,使这家总部位于波士顿的公司市值达到12.9亿美元。 Bicara公司在首次公开募股中以每股18美元的价格出售了1750万股股票,筹集了 3.15亿美元,这是其市场发行价范围的上限,此前Bicara公司曾两次增加。近几个月上市的药物开发商Alumis 和Artiva Biotherapeutics 的股价低于其IPO价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPG","BK4135","BCAX","LENZ","BK4139"],"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0},{"id":"2467170624","title":"由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467170624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467170624?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:14","pubTimestamp":1726247670,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月13日 - Bicara Therapeutics 的股价周五首次上市就上涨了45.8%,表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","BCAX","TPG","LENZ"],"gpt_icon":0},{"id":"2467270506","title":"更新 2-Zenas 生物制药公司首次上市股价上涨近 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2467270506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467270506?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:58","pubTimestamp":1726246693,"startTime":"0","endTime":"0","summary":" 路透9月13日 - 百时美施贵宝支持的Zenas生物制药公司 周五在纳斯达克首次公开发行股票 ,股价上涨近8%,这是2024年美国首次公开发行股票市场 在经历两年低迷后复苏的一个迹象。投资者对医疗支付公司 Waystar 和临床生物制药公司 CG Oncology 等公司反应热烈,截至上次收盘,这两家公司的交易价格均高于其 IPO 价格。Zenas与Bicara Therapeutics 和生物技术公司MBX Biosciences 同时上市,因为IPO活动在经历了夏季的低迷后有所回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","LU2360032135.SGD","IE00BJT1NW94.SGD","LU1291159041.SGD","BK4534","LU1585245621.USD","CGON","WAY","BK4585","BK4127","LU0061475181.USD","BMY","LU0225771236.USD","LU1261432733.SGD","LU0098860793.USD","LU0237698245.USD","IE0002141913.USD","IE00BZ1G4Q59.USD","LU0321505439.SGD","LU0868494617.USD","LU0106831901.USD","LU1093756168.USD","BK4559","LU1989772840.SGD","LU2357305700.SGD","LU0320765646.SGD","IPO","LU2125154935.USD","LU1093756325.SGD","BK4007","BCAX","BK4532","BK4077","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU1571399168.USD","LU1162221912.USD","LU2125154778.USD","LU2242646821.SGD","LU0882574055.USD","LU1989772923.USD","ZBIO","LU1989771016.USD","LU0267386448.USD","LU1548497426.USD","LU0321505868.SGD","LU1720051017.SGD","IE00BSNM7G36.USD","BK4167"],"gpt_icon":0},{"id":"2467689857","title":"TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467689857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467689857?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:22","pubTimestamp":1726190557,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月13日 - 由TPG支持的癌症疗法开发商Bicara Therapeutics 周四表示,它在美国的首次公开募股中筹集了3.15亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPG","BCAX","BK4135","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":0.0447},{"period":"1month","weight":0.4278},{"period":"ytd","weight":0.4278}],"compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0516},{"period":"6month","weight":0.0941},{"period":"1year","weight":0.3433},{"period":"ytd","weight":0.2041}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}